Beta Amyloid News and Research

RSS

Study uncovers a mechanism that explains calcium abnormalities in Alzheimer's brain

A new study uncovers a mechanism that directly links mutations that cause early onset Alzheimer's disease (AD) with aberrant calcium signaling. The research, published by Cell Press in the June 26th issue of the journal Neuron, provides exciting molecular insights into the pathology of AD and may lead to new treatment strategies.

25 Jun 2008

Early detection of Alzheimer's in the pipeline

A boost of $1.6 million for new research into Alzheimer's Disease for Australian scientists means that the early detection of the disease could well be in the pipeline.

19 Jun 2008

Molecular imaging helps follow the progression of Alzheimer's disease

In the past, physicians were able only to follow the progression of Alzheimer's disease (AD) through careful clinical histories, noting the often subtle changes associated with cognitive decline over a number of years.

16 Jun 2008

Researchers find gamma-secretase modulators being tested for Alzheimer’s work in unexpected and beneficial ways

Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.

11 Jun 2008

Australian researchers find important piece of Alzheimer's puzzle

Queensland Brain Institute (QBI) neuroscientists at UQ have discovered a new way to reduce neuronal loss in the brain of a person with Alzheimer's disease.

11 Jun 2008

Genetic variation linked to earlier onset of Alzheimer's symptoms

Investigators at Washington University School of Medicine in St. Louis have identified a genetic variation associated with an earlier age of onset in Alzheimer's disease.

9 Jun 2008

World's oldest woman had normal brain

A 115-year-old woman who remained mentally alert throughout her life had an essentially normal brain, with little or no evidence of Alzheimer's disease, according to a study in the August issue of Neurobiology of Aging.

9 Jun 2008

Rochester vaccine triggers immune response, prevents Alzheimer's

A vaccine created by University of Rochester Medical Center scientists prevents the development of Alzheimer's disease-like pathology in mice without causing inflammation or significant side effects.

19 May 2008

Patent claims allowed covering Samaritan's Alzheimer's memory recovery drug in Australia

Samaritan Pharmaceuticals, a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, has received notification that the claims in the patent application for "Neuroprotective Spirostenol Pharmaceutical Compositions" covering Caprospinol (SP-233) have been allowed by the Australian Patent Office.

6 May 2008

Alzheimer's and diabetes link

Diabetic individuals have a significantly higher risk of developing Alzheimer's disease but the molecular connection between the two remains unexplained. Now, researchers at the Salk Institute for Biological Studies identified the probable molecular basis for the diabetes - Alzheimer's interaction.

30 Apr 2008

Researchers close in on origins of main ingredient of Alzheimer's plaques

The ability of brain cells to take in substances from their surface is essential to the production of a key ingredient in Alzheimer's brain plaques, neuroscientists at Washington University School of Medicine in St. Louis have learned.

10 Apr 2008

Alzheimer's vaccine clears amyloid plaques but has little effect on learning and memory impairment

A promising vaccine being tested for Alzheimer's disease does what it is designed to do -- clear beta-amyloid plaques from the brain -- but it does not seem to help restore lost learning and memory abilities, according to a University of California, Irvine study.

7 Apr 2008

Eli Lilly starts trial of treatment of mild to moderate Alzheimer's disease

Eli Lilly and Company has announced the start of a Phase III clinical trial studying LY450139, an investigational gamma secretase inhibitor for the treatment of mild to moderate Alzheimer's disease.

1 Apr 2008

Groundbreaking study validates Pittsburgh Compound-B in identifying Alzheimer's disease brain toxins

A groundbreaking study conducted by University of Pittsburgh Alzheimer's disease researchers reported in the journal Brain (currently online) confirms that Pittsburgh Compound-B (PiB) binds to the telltale beta-amyloid deposits found in the brains of patients with Alzheimer's disease.

28 Mar 2008

New Alzheimer's patent by Affiris

Affiris GmbH has secured another Europe-wide patent for an innovative method of treating Alzheimer's disease. This new blood-cleansing method is similar to dialysis and is designed to reduce the amount of harmful protein deposits in the brain. It is based on the AFFITOME technology established by Affiris, which was patented in October 2007 for an Alzheimer's vaccine.

27 Feb 2008

Altering brain's lipid metabolism reduces Alzheimer's plaques in mice

Increasing levels of a protein that helps the brain use cholesterol may slow the development of Alzheimer's disease changes in the brain, according to researchers studying a mouse model of the disease at Washington University School of Medicine in St. Louis.

18 Jan 2008

Fish oil benefits

It's good news that we are living longer, but bad news that the longer we live, the better our odds of developing late-onset Alzheimer's disease.

28 Dec 2007

The blood-brain barrier: A misunderstood key to finding life-saving cures to brain disease

An international team of scientists that includes a Saint Louis University researcher suggest several strategies to propel research for treatments of brain diseases that include multiple sclerosis, Alzheimer's disease, obesity and stroke in the January issue of the Lancet Neurology.

20 Dec 2007

Study looks at progesterone for Alzheimer's

The first study on progesterone and Alzheimer's disease has found no clear preventive benefit for the widely prescribed hormone in an animal model.

27 Nov 2007

Affiris GmbH granted a Europe-wide patent for key elements of its Alzheimer's vaccine

As a result, the company has exclusive rights of use to the peptide sequences for an innovative approach to vaccine development. The tolerability of the first Affiris vaccine, AFFITOPE AD01, is currently being tested as part of a phase I clinical trial. The lead investor in the company, MIG-Fonds, is extremely satisfied with the expanding patent portfolio of Affiris GmbH.

21 Nov 2007